05.15.25 -- Trump-Era Tax Cuts Spark $27B U.S. Manufacturing Surge

With over 30+ years of experience, Catalent offers a comprehensive suite of orthogonal GMP analytical services for all biological modalities, from discovery to commercial phases. Our seasoned experts ensure exceptional on-time delivery and client satisfaction by providing tailored solutions to meet your unique needs—no matter the complexity, scale, or timeline. Watch our intro video to learn more about our capabilities!

Drive excellence in clinical trials by utilizing forecasting to better plan clinical supply budgets and project timelines, and identify potential supply-related issues before they negatively impact a study.

While clinical efficacy is the critical benchmark for any drug program, ensuring manufacturability is also vital. An experienced CDMO can help you establish efficient and cost-effective production strategies.

Learn about the cutting-edge technologies driving the shift to microbial expression and how the right outsourcing partner can help you leverage the benefits of these innovative therapeutics.

Novel technologies and therapies are helping drug developers to overcome challenges associated with the development of injectable and oral peptide formulations.

Examine a platform process that is emerging as a simplified and reliable solution for ADC manufacturing, offering efficient process development, purification techniques, and optimization strategies.

Delve into the specific advantages of dual-sourcing in pharmaceutical fill/finish, exploring how this approach can bolster supply chain resilience, increase capacity, and accelerate commercialization.

Utilize this approach in identifying potential product failure points and designing robust formulations and processes for lyophilized products backed by solid data.

Discover analytical strategies designed to address challenges occurring during development of new molecular formats such as chain assembly, multiple-MoAs, and diverse post-translational modifications.

Consider a solution that ensures particularly efficient and reliable vertical and horizontal form fill and seal machine labeling.

As biosimilar development continues to accelerate, with nearly $112 billion in biologic medicines set to lose exclusivity in the global market by 2025, the market is becoming increasingly competitive.

It is important to pursue a dualistic, longer-term supply strategy that embraces cost control and supply reliability/diversity to improve the integrity and resilience of international supply chains.

Recombinant protein production is evolving to meet growing demand. CHO-based systems remain central, but further innovation is needed. Join us on May 19th to learn how Lonza is enhancing its GS® expression vector technology with a high-strength synthetic promoter to boost yields, maintain quality, and support efficient biomanufacturing across diverse therapeutic proteins. Click here to register.

Finding a CDMO committed to increasing capacity and optimizing processes with innovative technologies is key for adding efficiency while maintaining high-quality standards.

Cytiva Supor™ Prime filters reduce product loss to waste, ensuring every drop counts towards maximizing your yield. Watch this product overview video to learn more.

This presentation from the July 2024 OPCU event discusses how unifying key functions, experience, and broad capabilities can accelerate more pipelines to market.

A strong manufacturing platform can make or break a biologic therapy — enabling rapid scaling, supply chain efficiency, faster therapy availability, and reduced shortage risk.

With cutting-edge technologies, regulatory excellence, and a commitment to quality, we provide seamless support tailored to your specific needs.